Boston Scientific Co. (NYSE:BSX) Shares Sold by Raymond James & Associates

Raymond James & Associates trimmed its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.1% during the second quarter, Holdings Channel.com reports. The firm owned 1,152,055 shares of the medical equipment provider’s stock after selling 12,648 shares during the quarter. Raymond James & Associates’ holdings in Boston Scientific were worth $88,720,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. CVA Family Office LLC raised its holdings in Boston Scientific by 7.4% during the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock worth $147,000 after purchasing an additional 131 shares in the last quarter. ST Germain D J Co. Inc. raised its stake in shares of Boston Scientific by 8.0% in the 2nd quarter. ST Germain D J Co. Inc. now owns 1,923 shares of the medical equipment provider’s stock worth $148,000 after buying an additional 143 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in shares of Boston Scientific by 2.0% in the first quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock valued at $512,000 after buying an additional 148 shares during the period. Transcend Capital Advisors LLC boosted its stake in Boston Scientific by 2.2% during the second quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 148 shares in the last quarter. Finally, KCM Investment Advisors LLC grew its holdings in Boston Scientific by 1.7% during the first quarter. KCM Investment Advisors LLC now owns 9,225 shares of the medical equipment provider’s stock worth $632,000 after acquiring an additional 150 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BSX shares. UBS Group upped their price target on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Raymond James increased their target price on shares of Boston Scientific from $85.00 to $91.00 and gave the company a “strong-buy” rating in a research note on Thursday, July 25th. Citigroup lifted their price target on shares of Boston Scientific from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. Truist Financial increased their price objective on Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, Mizuho raised their price objective on Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $84.76.

Boston Scientific Stock Up 0.9 %

Shares of BSX stock traded up $0.67 during trading on Friday, hitting $78.25. 4,414,404 shares of the company were exchanged, compared to its average volume of 6,225,274. The firm has a market capitalization of $114.80 billion, a price-to-earnings ratio of 65.76, a P/E/G ratio of 2.49 and a beta of 0.78. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The business’s 50-day simple moving average is $76.41 and its 200 day simple moving average is $71.94. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $79.43.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The company had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. During the same quarter last year, the business posted $0.53 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the transaction, the executive vice president now owns 40,188 shares in the company, valued at $2,978,734.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Boston Scientific news, EVP Arthur C. Butcher sold 14,011 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total value of $1,055,588.74. Following the completion of the sale, the executive vice president now owns 20,197 shares of the company’s stock, valued at $1,521,641.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the sale, the executive vice president now owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The disclosure for this sale can be found here. Insiders have sold 34,960 shares of company stock worth $2,638,984 over the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.